Singapore Markets close in 2 hrs 31 mins
DEALS:

Singtel takes 16.3% stake in Indonesia's Bank Fama for S$48 million

Apexigen to Participate in the 2021 Wedbush PacGrow Healthcare Conference

·1-min read

SAN CARLOS, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.

Wedbush PacGrow Healthcare Conference

Panel discussion: For Your IOnly – Progress, Challenges in Immuno-Oncology

Wednesday, August 11, 2021, at 12:35 p.m. ET

The webcast of the Wedbush panel discussion will be accessible in the News & Events section of the Apexigen website at https://www.apexigen.com.

About Apexigen
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Sotigalimab and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product or product candidates discovered using APXiMAB are currently commercially available or in clinical development, either internally by Apexigen or by its licensees. For more information, please visit www.apexigen.com.

Investor Contact:
Bruce Mackle
LifeSci Advisors
+1-646-889-1200
bmackle@lifesciadvisors.com

Apexigen Contact:
Mark Nevins
Sr. Vice President, Business Development
Apexigen, Inc.
+1-650-931-6236
mnevins@apexigen.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting